Page last updated: 2024-11-04

lapachol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lapachol is a naturally occurring naphthoquinone compound found in the heartwood and bark of various trees of the genus *Tabebuia*, notably *Tabebuia impetiginosa* (Pau d’arco) and *Tabebuia serratifolia*. It has garnered significant scientific interest due to its diverse biological activities, including potent anti-inflammatory, antimicrobial, anticancer, and antioxidant properties. Lapachol exhibits its therapeutic effects through multiple mechanisms, including modulation of reactive oxygen species (ROS) production, inhibition of various enzymes, and interference with cell signaling pathways. The compound has been shown to possess cytotoxic effects against a range of cancer cells, including leukemia, melanoma, and breast cancer. Lapachol's unique structure and diverse pharmacological activities have fueled research into its potential therapeutic applications. However, further investigation is required to optimize its pharmacokinetic properties and address potential toxicity concerns before it can be safely and effectively used in clinical settings.'

lapachol : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone substituted by hydroxy and 3-methylbut-2-en-1-yl groups at positions 2 and 3, respectively. It is a natural compound that exhibits antibacterial and anticancer properties, first isolated in 1882 from the bark of Tabebuia avellanedae. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3884
CHEMBL ID15193
CHEBI ID6377
SCHEMBL ID157255
SCHEMBL ID157256
MeSH IDM0051942

Synonyms (102)

Synonym
nsc-629756
1,4-naphthalenedione, 2-hydroxy-3-(3-methyl-2-butenyl)-
1,4-naphthoquinone, 2-hydroxy-3-(3-methyl-2-butenyl)-
DIVK1C_000594
KBIO1_000594
NCIMECH_000076
SDCCGMLS-0066666.P001
2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthalenedione
2-hydroxy-3-(3-methylbut-2-enyl)-1,4-naphthoquinone
zlut prirodni 16 [czech]
nsc 629756
lapachic acid
ccris 745
greenharten
tecomin (van)
brn 2051889
einecs 201-563-7
ipe-tobacco wood
greenhartin
wln: l66 bv evj cq d2uy1&1
nsc 11905
2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone
nsc11905 ,
1, 2-hydroxy-3-(3-methyl-2-butenyl)-
surinam greenheart wood
taiguic acid
nsc-11905
lapachol wood
taigu wood
c.i. natural yellow 16
c.i. 75490
bethabarra wood
cancer chemother rep (part 2) 4: 11 (1974)
SPECTRUM5_001873
2-hydroxy-3-(3-methylbut-2-enyl)naphthalene-1,4-dione
NSC629756 ,
IDI1_000594
BSPBIO_002416
lapachol
84-79-7
lapachol, 98%
NCGC00094931-02
NCGC00094931-01
KBIO3_001636
NCI60_000457
NCI60_000587
SPECTRUM2_001451
SPBIO_001341
SPECTRUM3_000768
NINDS_000594
SPECTRUM1501204
OPREA1_717083
NCGC00094931-04
NCGC00094931-03
CHEMBL15193
chebi:6377 ,
HMS501N16
HMS1921B06
4-hydroxy-3-(3-methylbut-2-enyl)naphthalene-1,2-dione
4-08-00-02487 (beilstein handbook reference)
zlut prirodni 16
b221938vb6 ,
unii-b221938vb6
dtxcid5029390
NCGC00260494-01
tox21_202948
dtxsid6049430 ,
cas-84-79-7
BMSE000989
natural yellow-?16
AKOS015951424
CCG-35464
FT-0649649
lapachol [mi]
ci 75490
2-hydroxy-3-(3-methyl-2-buten-1-yl)-1,4-naphthalenedione
S5684
1,4-naphthalenedione,2-hydroxy-3-(3-methyl-2-buten-1-yl)-
SCHEMBL157255
SCHEMBL157256
2-hydroxy-3-(3-methyl-2-butenyl)naphthoquinone #
mfcd00001679
AC-8971
sr-05000002489
SR-05000002489-1
groenhartin
lapachoic acid
ci75490
AKOS032948320
BCP24022
nsc-11905; nsc 11905; nsc11905
2-hydroxy-3-(3-methylbut-2-en-1-yl)naphthalene-1,4-dione
AS-35308
Q739601
HMS3869D03
AMY40588
CS-W020951
A863979
NCGC00094931-06
HY-N6961
4-hydroxy-3-(3-methylbut-2-en-1-yl)-1,2-dihydronaphthalene-1,2-dione
PD087478

Research Excerpts

Overview

Lapachol is an abundant prenyl naphthoquinone occurring in Brazilian Bignoniaceae. It was clinically used, in former times, as an antimalarial drug, despite its moderate effect. Lapachol kills several types of cancer cells.

ExcerptReferenceRelevance
"Lapachol is an abundant prenyl naphthoquinone occurring in Brazilian Bignoniaceae that was clinically used, in former times, as an antimalarial drug, despite its moderate effect. "( Antimalarial naphthoquinones. Synthesis via click chemistry, in vitro activity, docking to PfDHODH and SAR of lapachol-based compounds.
Arantes, LM; Braga de Oliveira, A; Brandão, GC; Doerksen, RJ; Pereira, GR; Rocha Missias, FC; Roy, KK; Soares, LF, 2018
)
2.14
"Lapachol is a plant-derived naphthoquinone that kills several types of cancer cells. "( Lapachol acetylglycosylation enhances its cytotoxic and pro-apoptotic activities in HL60 cells.
Alves, RJ; de Sousa, FS; de Victo, NC; Holzer, AK; Kisitu, J; Leist, M; Marques, LB; Ottoni, FM; Pinto, MCX; Ribeiro, JM; Souza-Fagundes, EM; Weinlich, R, 2020
)
3.44
"Lapachol (LAP) is a natural compound with various biological properties, including anticancer activity. "( Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model.
Alcântara Lemos, J; Alves, RJ; Cassali, GD; de Barros, ALB; Fernandes, RS; Ferreira, LAM; Mendes Miranda, SE; Ottoni, FM; Rubello, D; Silva, JO; Townsend, DM, 2021
)
2.35
"Lapachol is a 1,4- naphthoquinone compound that has been demonstrated to have therapeutic effects against several diseases."( In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2.
Aguiar, RS; Jardim, ACG; José, DP; Junior, NN; Lapa, IR; Meireles, BA; Nicolau, MSP; Santos, IA, 2022
)
1.75
"Lapachol is a natural compound, belonging to the naphthoquinone group that has been widely used in traditional medicine to treat various illnesses, including cancer."( Technetium-99m-labeled lapachol as an imaging probe for breast tumor identification.
Alves, RJ; Branco de Barros, AL; Cardoso, VN; Fernandes, RS; Ferretti, A; Lemos, JA; Miranda, SE; Ottoni, FM; Rubello, D,
)
1.16
"Lapachol is a natural naphthoquinone with a range of biological effects, including anticancer activity. "( Lapachol biotransformation by filamentous fungi yields bioactive quinone derivatives and lapachol-stimulated secondary metabolites.
Barbosa Coitinho, L; Cabral, H; da Rosa-Garzon, NG; da Silva Emery, F; Fumagalli, F, 2019
)
3.4
"Lapachol is a 1,4-naphthoquinone that is isolated from the Bignoniaceae family. "( Lapachol is a novel ribosomal protein S6 kinase 2 inhibitor that suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells.
Bode, AM; Dong, Z; Kim, DJ; Liu, K; Xie, X; Zhang, Y; Zu, X, 2019
)
3.4
"Lapachol is a natural naphthoquinone compound derived from Bignoniaceae (Tabebuia sp.) that possesses a range of significant biological activities. "( Structural elucidation of the metabolites of lapachol in rats by liquid chromatography-tandem mass spectrometry.
Bai, L; Han, Y; Li, X; Li, Y; Xu, P; Xue, M; Yao, J, 2014
)
2.1
"Lapachol is a natural naphthoquinone compound that possesses extensive biological activities. "( Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II.
Bai, L; Chen, Q; Li, X; Wang, H; Xu, H; Xu, P; Xue, M; Yuan, R, 2016
)
2.19
"Lapachol is a naturally occurring naphthoquinone derivative found in the heartwood of several plants, particularly those of the genus Tabebuia (Bignoneaceae). "( Lapachol induces clastogenic effects in rats.
Andrade, SF; Fernandes, DM; Maistro, EL; Pereira, FM, 2010
)
3.25
"Lapachol is a naphthoquinone well known for its therapeutic potential. "( Fetal growth in rats treated with lapachol.
Brandão, MA; Chang, CV; Felício, AC; Guerra, Mde O; Peters, VM, 2002
)
2.04
"Lapachol is a therapeutic naphthoquinone, but little is known about its general and reproductive toxicity. "( Reproductive toxicity of lapachol in adult male Wistar rats submitted to short-term treatment.
de Cássia da Silveira E Sá, R; de Oliveira Guerra, M, 2007
)
2.09
"Lapachol is a naphtoquinone with therapeutic potential against Chagas disease and is also used as an antimalarial agent. "( Interceptive effect of Lapachol in rats.
Brandão, MA; Guerra, MO; Mazoni, AS; Peters, VM, 1999
)
2.06
"Lapachol is a naphtoquinone with therapeutic potential against enterovirus, Chagas disease and is also used as an antimalarial and antiinflamatory agent. "( Toxicology of Lapachol in rats: embryolethality.
Brandão, MA; Guerra, Mde O; Mazoni, AS; Peters, VM, 2001
)
2.11

Effects

ExcerptReferenceRelevance
"Lapachol has been found to be a potent inhibitor of the enzyme DT-Diaphorase. "( Lapachol inhibition of DT-diaphorase (NAD(P)H:quinone dehydrogenase).
Preusch, PC, 1986
)
3.16

Actions

ExcerptReferenceRelevance
"Lapachol could inhibit the activities of both TOP I and II."( Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II.
Bai, L; Chen, Q; Li, X; Wang, H; Xu, H; Xu, P; Xue, M; Yuan, R, 2016
)
1.47

Treatment

Lapachol treatment also inhibited COL1A1 and PAI-1 mRNA levels in hypertrophic scar fibroblasts. Treatment did not affect IL-6 mRNA levels.

ExcerptReferenceRelevance
"Lapachol treatment also inhibited COL1A1 and PAI-1 mRNA levels in hypertrophic scar fibroblasts, but did not affect IL-6 mRNA levels."( Lapachol suppresses cell proliferation and secretion of interleukin-6 and plasminogen activator inhibitor-1 of fibroblasts derived from hypertrophic scars.
Furukawa, H; Ito, C; Itoigawa, M; Matsui, T; Oda, M; Okada, T; Yokoo, K, 2011
)
2.53
"treated with lapachol and [Bi(Lp)(2)]Cl while in the per os treatment inhibition was observed only for [Bi(Lp)(2)]Cl."( Coordination of lapachol to bismuth(III) improves its anti-inflammatory and anti-angiogenic activities.
Andrade, SP; Beraldo, H; Campos, PP; Duarte, LP; Parrilha, GL; Silva, GD; Vieira, RP, 2012
)
1.08

Toxicity

ExcerptReferenceRelevance
"54 ppm), differently from the potassium salt of lapachol that can be considered non toxic (LC90=176."( Toxicity of lapachol and isolapachol and their potassium salts against Biomphalaria glabrata, Schistosoma mansoni cercariae, Artemia salina and Tilapia nilotica.
dos Santos, AF; Goulart, MO; Lima, NM; Porfírio, Z; Sant'Ana, AE, 2002
)
0.95

Bioavailability

ExcerptReferenceRelevance
" Nanoemulsions are drug delivery systems that can assist in the administration of hydrophobic drugs, increasing their bioavailability and protecting from degradation."( Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model.
Alcântara Lemos, J; Alves, RJ; Cassali, GD; de Barros, ALB; Fernandes, RS; Ferreira, LAM; Mendes Miranda, SE; Ottoni, FM; Rubello, D; Silva, JO; Townsend, DM, 2021
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (60)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency4.46680.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency1.44670.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.37090.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency79.25110.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency79.25110.002541.796015,848.9004AID1347395; AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency14.43180.006038.004119,952.5996AID1159521; AID1159523
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency27.51100.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency47.65540.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency21.97310.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency20.94540.000221.22318,912.5098AID1259247; AID1259381; AID743035; AID743053; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency68.17130.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency49.55170.001022.650876.6163AID1224838; AID1224839; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency1.93890.000214.376460.0339AID720692
retinoid X nuclear receptor alphaHomo sapiens (human)Potency3.44790.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency2.28110.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency1.09030.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency19.21330.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.51930.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743080; AID743091
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency0.77190.001019.414170.9645AID743191
caspase-3Homo sapiens (human)Potency68.17130.013326.981070.7614AID1346978
aryl hydrocarbon receptorHomo sapiens (human)Potency38.71390.000723.06741,258.9301AID743085; AID743122
thyroid stimulating hormone receptorHomo sapiens (human)Potency40.93680.001628.015177.1139AID1224843; AID1224895; AID1259385
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency15.79770.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency62.65600.039147.5451146.8240AID1224845; AID1224896
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency2.51190.316212.443531.6228AID902
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency30.30010.354828.065989.1251AID504847
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.17120.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency62.76520.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency27.40160.00798.23321,122.0200AID2546; AID2551
survival motor neuron protein isoform dHomo sapiens (human)Potency3.57170.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency4.82620.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency1.80040.002319.595674.0614AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency4.82620.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency12.58931.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydroorotate dehydrogenase Schistosoma mansoniIC50 (µMol)0.01900.01901.94088.8000AID1592257
M-phase inducer phosphatase 1Homo sapiens (human)IC50 (µMol)33.20000.02204.20249.4000AID1517763
M-phase inducer phosphatase 2Homo sapiens (human)IC50 (µMol)42.70000.10002.31039.5100AID1517765
Dihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)IC50 (µMol)0.10000.00050.742710.0000AID1592258
Lactoylglutathione lyaseHomo sapiens (human)Ki37.15350.00122.59479.1400AID74123
Cysteine protease Trypanosoma brucei rhodesienseIC50 (µMol)79.00000.00313.87667.7500AID1754249; AID1754257
G-protein coupled receptor 35Homo sapiens (human)IC50 (µMol)4.66000.03001.39804.6600AID663960
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled receptor 35Homo sapiens (human)EC50 (µMol)25.37000.00202.50079.8000AID663955; AID663956
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (156)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityM-phase inducer phosphatase 1Homo sapiens (human)
G1/S transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
cell population proliferationM-phase inducer phosphatase 1Homo sapiens (human)
response to radiationM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
cellular response to UVM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of DNA replicationM-phase inducer phosphatase 1Homo sapiens (human)
cell divisionM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
oocyte maturationM-phase inducer phosphatase 2Homo sapiens (human)
protein phosphorylationM-phase inducer phosphatase 2Homo sapiens (human)
female meiosis IM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of cell population proliferationM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of cytokinesisM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
cell divisionM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
UDP biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
'de novo' UMP biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
pyrimidine ribonucleotide biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
'de novo' pyrimidine nucleobase biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
carbohydrate metabolic processLactoylglutathione lyaseHomo sapiens (human)
regulation of transcription by RNA polymerase IILactoylglutathione lyaseHomo sapiens (human)
glutathione metabolic processLactoylglutathione lyaseHomo sapiens (human)
methylglyoxal metabolic processLactoylglutathione lyaseHomo sapiens (human)
osteoclast differentiationLactoylglutathione lyaseHomo sapiens (human)
negative regulation of apoptotic processLactoylglutathione lyaseHomo sapiens (human)
cytoskeleton organizationG-protein coupled receptor 35Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationG-protein coupled receptor 35Homo sapiens (human)
chemokine-mediated signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
negative regulation of voltage-gated calcium channel activityG-protein coupled receptor 35Homo sapiens (human)
negative regulation of neuronal action potentialG-protein coupled receptor 35Homo sapiens (human)
positive regulation of Rho protein signal transductionG-protein coupled receptor 35Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (43)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
phosphoprotein phosphatase activityM-phase inducer phosphatase 1Homo sapiens (human)
protein tyrosine phosphatase activityM-phase inducer phosphatase 1Homo sapiens (human)
protein bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein kinase bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein-folding chaperone bindingM-phase inducer phosphatase 1Homo sapiens (human)
phosphoprotein phosphatase activityM-phase inducer phosphatase 2Homo sapiens (human)
protein tyrosine phosphatase activityM-phase inducer phosphatase 2Homo sapiens (human)
protein bindingM-phase inducer phosphatase 2Homo sapiens (human)
protein kinase bindingM-phase inducer phosphatase 2Homo sapiens (human)
dihydroorotase activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
protein bindingDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
dihydroorotate dehydrogenase (quinone) activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
dihydroorotate dehydrogenase activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
lactoylglutathione lyase activityLactoylglutathione lyaseHomo sapiens (human)
protein bindingLactoylglutathione lyaseHomo sapiens (human)
zinc ion bindingLactoylglutathione lyaseHomo sapiens (human)
C-X-C chemokine receptor activityG-protein coupled receptor 35Homo sapiens (human)
G protein-coupled receptor activityG-protein coupled receptor 35Homo sapiens (human)
C-X-C chemokine receptor activityG-protein coupled receptor 35Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleoplasmM-phase inducer phosphatase 1Homo sapiens (human)
cytosolM-phase inducer phosphatase 1Homo sapiens (human)
nucleusM-phase inducer phosphatase 1Homo sapiens (human)
cytoplasmM-phase inducer phosphatase 1Homo sapiens (human)
spindle poleM-phase inducer phosphatase 2Homo sapiens (human)
nucleoplasmM-phase inducer phosphatase 2Homo sapiens (human)
centrosomeM-phase inducer phosphatase 2Homo sapiens (human)
cytosolM-phase inducer phosphatase 2Homo sapiens (human)
nucleusM-phase inducer phosphatase 2Homo sapiens (human)
cytoplasmM-phase inducer phosphatase 2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleoplasmDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrionDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrial inner membraneDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
cytosolDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrial inner membraneDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
nucleoplasmLactoylglutathione lyaseHomo sapiens (human)
cytoplasmLactoylglutathione lyaseHomo sapiens (human)
cytosolLactoylglutathione lyaseHomo sapiens (human)
plasma membraneLactoylglutathione lyaseHomo sapiens (human)
extracellular exosomeLactoylglutathione lyaseHomo sapiens (human)
plasma membraneG-protein coupled receptor 35Homo sapiens (human)
plasma membraneG-protein coupled receptor 35Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (148)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID158817Inhibition of Plasmodium berghei infection in mice (Mus musculus) at 200 mg/kg peroral dose (expt 2)2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Antimalarial activity of phenazines from lapachol, beta-lapachone and its derivatives against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1667215Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 12.5 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to contr2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID744772Antileishmanial activity against antimony-sensitive Leishmania infantum MCAN/BR/2002/BH400 promastigote infected in Swiss mouse peritoneal macrophages after 72 hrs2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID324608Effect on oxygen redox cycling in Trypanosoma cruzi Tulahuen assessed as oxygen consumption per mg of protein relative to control2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID1517784Cytotoxicity against human LS174T cells assessed as reduction in cell viability at <50 uM incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1657056Inhibition of IL-6 induced STAT3 phosphorylation at Tyr705 residue in human MCF7 cells at 1 uM preincubated for 1 hr followed by IL-6 stimulation and measured after 1 hr by Western blot analysis relative to control2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
STAT3 inhibitory activity of naphthoquinones isolated from Tabebuia avellanedae.
AID1517778Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability at <50 uM incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID714733Plasma concentration in Wistar rat at 25 mg/kg after 12 hrs2012European journal of medicinal chemistry, Aug, Volume: 54Biomimetic in vitro oxidation of lapachol: a model to predict and analyse the in vivo phase I metabolism of bioactive compounds.
AID735529Cytotoxicity against human WHCO1 cells after 24 hrs by MTT assay2013European journal of medicinal chemistry, Apr, Volume: 62Cytotoxicity of lapachol, β-lapachone and related synthetic 1,4-naphthoquinones against oesophageal cancer cells.
AID451343Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio after 48 hrs by trypan blue staining2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID303294Inhibition of TPA-induced EBV-EA activation in Raji cells at 100 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID476714Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol.
AID744767Selectivity index, ratio of CC50 for Swiss mouse peritoneal macrophages to IC50 for antimony-sensitive Leishmania infantum MCAN/BR/2002/BH400 promastigote2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID303299Cell viability in Raji cells at 100 mol ratio/TPA by tryptan blue staining relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID1754260Reversible inhibition of recombinant Trypanosoma brucei rhodesain using Z-FR-AMC as substrate measured for 30 mins by fluorimetric analysis
AID476716Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol.
AID1356022Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1517777Cytotoxicity against human THP1 cells assessed as reduction in cell viability at <50 uM incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID744766Selectivity index, ratio of CC50 for Swiss mouse peritoneal macrophages to IC50 for antimony-resistant Leishmania infantum MCAN/BR/2002/BH400 promastigote2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID1657059Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
STAT3 inhibitory activity of naphthoquinones isolated from Tabebuia avellanedae.
AID1517785Cytotoxicity against human A549 cells assessed as reduction in cell viability at <50 uM incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID277224Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Synthesis and pharmacophore modeling of naphthoquinone derivatives with cytotoxic activity in human promyelocytic leukemia HL-60 cell line.
AID1517787Binding affinity to MKK7 (unknown origin) expressed in HEK293 cells assessed as dissociation constant at <30 uM by kinomescan method2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1754256Inhibition of recombinant Trypanosoma brucei rhodesain at 100 uM using Z-FR-AMC as substrate by fluorimetric analysis
AID1858852Cytotoxicity against human A549 cells incubated for 24 hrs by MTT assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID714732Metabolic stability in in Wistar rat plasma assessed as alpha-lapachone level at 25 mg/kg after 3 hrs2012European journal of medicinal chemistry, Aug, Volume: 54Biomimetic in vitro oxidation of lapachol: a model to predict and analyse the in vivo phase I metabolism of bioactive compounds.
AID665100Growth inhibition of human HeLa cells by SRB assay2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID1517783Cytotoxicity against human MCF7 cells assessed as reduction in cell viability at <50 uM incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID618760Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis ATCC 35822 harboring Ser-315-Tri mutation in katG gene after 9 days by resazurin reduction assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Quinonoid and phenazine compounds: synthesis and evaluation against H37Rv, rifampicin and isoniazid-resistance strains of Mycobacterium tuberculosis.
AID744770Antileishmanial activity against antimony-sensitive Leishmania amazonensis MHOM/BR/1989/BA199 promastigote infected in Swiss mouse peritoneal macrophages after 72 hrs2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID303296Inhibition of TPA-induced EBV-EA activation in Raji cells2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID324607Effect on oxygen uptake per mg of protein in Trypanosoma cruzi Tulahuen epimastigotes relative to control2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID1517790Inhibition of recombinant HNE (unknown origin) at <50 uM using N-methylsuccinyl-Ala-Ala-Pro-Val-7-amino-4-methylcoumarin, as a substrate measured every 30 sec for 10 mins by fluorometric assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1592257Inhibition of Schistosoma mansoni DHODH using DHO as substrate measured at 4 secs interval for 60 secs by DCIP reduction based indirect assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Ligand-based design, synthesis and biochemical evaluation of potent and selective inhibitors of Schistosoma mansoni dihydroorotate dehydrogenase.
AID665101Growth inhibition of human SW1573 cells by SRB assay2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID744771Antileishmanial activity against antimony-resistant Leishmania infantum MCAN/BR/2002/BH400 promastigote infected in Swiss mouse peritoneal macrophages after 72 hrs2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID663961Agonist activity at GPR35 receptor in human HT-29 cells assessed as shift in resonant wavelength of biosensor stimulation after 10 mins by dynamic mass redistribution assay relative to control2012ACS medicinal chemistry letters, Feb-09, Volume: 3, Issue:2
Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists.
AID1592258Inhibition of human DHODH using DHO as substrate measured at 4 secs interval for 60 secs by DCIP reduction based indirect assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Ligand-based design, synthesis and biochemical evaluation of potent and selective inhibitors of Schistosoma mansoni dihydroorotate dehydrogenase.
AID1064150Growth inhibition of human LoVo cells by MTT assay2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Growth inhibitory activity for cancer cell lines of lapachol and its natural and semi-synthetic derivatives.
AID1403756Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Antimalarial naphthoquinones. Synthesis via click chemistry, in vitro activity, docking to PfDHODH and SAR of lapachol-based compounds.
AID380857Cytotoxicity against human HaCaT cells assessed as LDH release at 2 uM1999Journal of natural products, Aug, Volume: 62, Issue:8
Potential antipsoriatic agents: lapacho compounds as potent inhibitors of HaCaT cell growth.
AID400160Cytotoxicity against human KB cells
AID481798Antitrypanosomal activity against Trypanosoma cruzi Y blood stream trypomastigotes after 24 hrs2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
The evaluation of quinonoid compounds against Trypanosoma cruzi: synthesis of imidazolic anthraquinones, nor-beta-lapachone derivatives and beta-lapachone-based 1,2,3-triazoles.
AID1517782Cytotoxicity against human U937 cells assessed as reduction in cell viability at <50 uM incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1403755Antimalarial activity against chloroquine-resistant/mefloquine-sensitive Plasmodium falciparum W2 ring stage forms infected in human erythrocytes assessed as reduction in parasite growth after 48 hrs by parasite LDH release assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Antimalarial naphthoquinones. Synthesis via click chemistry, in vitro activity, docking to PfDHODH and SAR of lapachol-based compounds.
AID1356021Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID277223Cytotoxicity against human promyelocytic leukemia HL60 cell line by MTT assay2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Synthesis and pharmacophore modeling of naphthoquinone derivatives with cytotoxic activity in human promyelocytic leukemia HL-60 cell line.
AID1705065Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoi2020European journal of medicinal chemistry, Dec-15, Volume: 208Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors.
AID303295Inhibition of TPA-induced EBV-EA activation in Raji cells at 10 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID481799Cytotoxicity against human PBMC after 72 hrs by alamar blue assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
The evaluation of quinonoid compounds against Trypanosoma cruzi: synthesis of imidazolic anthraquinones, nor-beta-lapachone derivatives and beta-lapachone-based 1,2,3-triazoles.
AID723185Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream trypomastigotes isolated from infected Swiss mouse blood assessed as lysis level after 24 hrs2013European journal of medicinal chemistry, Feb, Volume: 60Synthesis and biological activity against Trypanosoma cruzi of substituted 1,4-naphthoquinones.
AID1517765Inhibition of recombinant Cdc25B (unknown origin) using OMFP as substrate measured every 30 sec for 10 mins by fluorometric assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1064155Growth inhibition of human A549 cells by MTT assay2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Growth inhibitory activity for cancer cell lines of lapachol and its natural and semi-synthetic derivatives.
AID1657061Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
STAT3 inhibitory activity of naphthoquinones isolated from Tabebuia avellanedae.
AID1322188Cytotoxicity against HEEC assessed as decrease in cell proliferation after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Design, synthesis and biological evaluation of lapachol derivatives possessing indole scaffolds as topoisomerase I inhibitors.
AID337793Cytotoxicity against mouse P388 cells
AID1858855Antimalarial activity against Plasmodium falciparum W2 incubated for 24 hrs2021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID618758Antitubercular activity against Mycobacterium tuberculosis H37Rv after 9 days by resazurin reduction assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Quinonoid and phenazine compounds: synthesis and evaluation against H37Rv, rifampicin and isoniazid-resistance strains of Mycobacterium tuberculosis.
AID476717Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol.
AID380856Antiproliferative activity against human HaCaT cells1999Journal of natural products, Aug, Volume: 62, Issue:8
Potential antipsoriatic agents: lapacho compounds as potent inhibitors of HaCaT cell growth.
AID1858853Cytotoxicity against human LLC-PK1 cells incubated for 24 hrs by MTT assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID1064152Growth inhibition of human SK-MEL-28 cells by MTT assay2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Growth inhibitory activity for cancer cell lines of lapachol and its natural and semi-synthetic derivatives.
AID324606Antitrypanosomal activity against Trypanosoma cruzi Tulahuen assessed as trypomastigote viability at 31.3 uM by MTT assay relative to control2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID1754257Inhibition of recombinant Trypanosoma brucei rhodesain using Z-FR-AMC as substrate by fluorimetric analysis relative to control
AID714735Toxicity in Wistar rat at 25 mg/kg2012European journal of medicinal chemistry, Aug, Volume: 54Biomimetic in vitro oxidation of lapachol: a model to predict and analyse the in vivo phase I metabolism of bioactive compounds.
AID1657057Inhibition of IL-6 induced STAT3 phosphorylation at Tyr705 residue in human MCF7 cells at 10 uM preincubated for 1 hr followed by IL-6 stimulation and measured after 1 hr by Western blot analysis relative to control2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
STAT3 inhibitory activity of naphthoquinones isolated from Tabebuia avellanedae.
AID1064154Growth inhibition of human U373 cells by MTT assay2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Growth inhibitory activity for cancer cell lines of lapachol and its natural and semi-synthetic derivatives.
AID744765Selectivity index, ratio of CC50 for Swiss mouse peritoneal macrophages to IC50 for antimony-sensitive Leishmania amazonensis MHOM/BR/1989/BA199 promastigote2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID303293Inhibition of TPA-induced EBV-EA activation in Raji cells at 500 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID744769Antileishmanial activity against antimony-resistant Leishmania amazonensis MHOM/BR/1989/BA199 promastigote infected in Swiss mouse peritoneal macrophages after 72 hrs2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID476718Toxicity in Artemia salina2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol.
AID333842Cytotoxicity against human KB cells
AID1592253Inhibition of Schistosoma mansoni DHODH assessed as remaining enzyme activity at 250 uM using DHO as substrate measured at 4 secs interval for 60 secs by DCIP reduction based indirect assay relative to control2019European journal of medicinal chemistry, Apr-01, Volume: 167Ligand-based design, synthesis and biochemical evaluation of potent and selective inhibitors of Schistosoma mansoni dihydroorotate dehydrogenase.
AID451330Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID665102Growth inhibition of human WiDr cells by SRB assay2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID1657060Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
STAT3 inhibitory activity of naphthoquinones isolated from Tabebuia avellanedae.
AID1754249Inhibition of recombinant Trypanosoma brucei rhodesain using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition measured for 5 mins by fluorimetric analysis relative to control
AID382236Trypanocidal activity against Trypanosoma cruzi Y blood stream trypomastigotes after 24 hrs2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Synthesis and anti-Trypanosoma cruzi activity of derivatives from nor-lapachones and lapachones.
AID389438Anticancer activity against human DU145 cells after 72 hrs 25 ug/ml by XTT assay2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Semisynthesis and antitumoral activity of 2-acetylfuranonaphthoquinone and other naphthoquinone derivatives from lapachol.
AID451329Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID744764Selectivity index, ratio of CC50 for Swiss mouse peritoneal macrophages to IC50 for antimony-resistant Leishmania amazonensis MHOM/BR/1989/BA199 promastigote2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID451338Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 1000 molar ratio after 48 hrs by immunofluorescence technique relative to 12-O-tetradecanoylphorbol-13-acetate2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID714729Metabolic stability in in Wistar rat plasma assessed as alpha-lapachone level at 25 mg/kg after 12 hrs2012European journal of medicinal chemistry, Aug, Volume: 54Biomimetic in vitro oxidation of lapachol: a model to predict and analyse the in vivo phase I metabolism of bioactive compounds.
AID663964Agonist activity at GPR35 receptor in human HT-29 cells at 8 uM after 10 mins by dynamic mass redistribution assay in the presence of SPB051422012ACS medicinal chemistry letters, Feb-09, Volume: 3, Issue:2
Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists.
AID1754248Inhibition of recombinant Trypanosoma brucei rhodesain at 100 uM using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition measured for 5 mins by fluorimetric analysis relative to control
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID451339Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 500 molar ratio after 48 hrs by immunofluorescence technique relative to 12-O-tetradecanoylphorbol-13-acetate2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID1517780Cytotoxicity against human SW982 cells assessed as reduction in cell viability at <50 uM incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID476712Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol.
AID714730Metabolic stability in in Wistar rat plasma assessed as dehydro-alpha-lapachone level at 25 mg/kg after 1.5 hrs2012European journal of medicinal chemistry, Aug, Volume: 54Biomimetic in vitro oxidation of lapachol: a model to predict and analyse the in vivo phase I metabolism of bioactive compounds.
AID1667214Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 25 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID714734Plasma concentration in Wistar rat at 25 mg/kg after 1.5 hrs2012European journal of medicinal chemistry, Aug, Volume: 54Biomimetic in vitro oxidation of lapachol: a model to predict and analyse the in vivo phase I metabolism of bioactive compounds.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1858851Cytotoxicity against human HepG2 cells incubated for 24 hrs by MTT assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID476715Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol.
AID389437Anticancer activity against human DU145 cells after 72 hrs by XTT assay2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Semisynthesis and antitumoral activity of 2-acetylfuranonaphthoquinone and other naphthoquinone derivatives from lapachol.
AID324605Growth inhibition of Trypanosoma cruzi Tulahuen epimastigotes assessed as drug level causing decrease in growth constant2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID663960Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins2012ACS medicinal chemistry letters, Feb-09, Volume: 3, Issue:2
Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists.
AID1592259Selectivity Index, ratio of IC50 for human DHODH to IC50 for Schistosoma mansoni DHODH2019European journal of medicinal chemistry, Apr-01, Volume: 167Ligand-based design, synthesis and biochemical evaluation of potent and selective inhibitors of Schistosoma mansoni dihydroorotate dehydrogenase.
AID1312268Inhibition of LPS-induced TNF-alpha production in human PBMC at 1 to 100 uM administered prior to LPS-challenge measured after 2 hrs by ELISA2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Anti-inflammatory properties of pterocarpanquinone LQB-118 in mice.
AID663962Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay relative to control2012ACS medicinal chemistry letters, Feb-09, Volume: 3, Issue:2
Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists.
AID451340Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 100 molar ratio after 48 hrs by immunofluorescence technique relative to 12-O-tetradecanoylphorbol-13-acetate2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID1517781Cytotoxicity against human Jurkat cells assessed as reduction in cell viability at <50 uM incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID451342Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells after 48 hrs by immunofluorescence technique2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID451341Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 10 molar ratio after 48 hrs by immunofluorescence technique relative to 12-O-tetradecanoylphorbol-13-acetate2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID665099Growth inhibition of human HBL100 cells by SRB assay2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID1754255Inhibition of recombinant Trypanosoma brucei rhodesain at 100 uM using Z-FR-AMC as substrate by fluorimetric analysis relative to control
AID451331Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID476713Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol.
AID158818Inhibition of Plasmodium berghei infection in mice (Mus musculus) at 200 mg/kg peroral dose (experiment 3); Not determined2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Antimalarial activity of phenazines from lapachol, beta-lapachone and its derivatives against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1403757Selectivity index, CC50 for human HepG2 cells to IC50 for chloroquine-resistant/mefloquine-sensitive Plasmodium falciparum W2 ring stage forms2018European journal of medicinal chemistry, Feb-10, Volume: 145Antimalarial naphthoquinones. Synthesis via click chemistry, in vitro activity, docking to PfDHODH and SAR of lapachol-based compounds.
AID95651Evaluated for cytotoxicity in the KB cell culture assay1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Antitumor agents. 89. Psychorubrin, a new cytotoxic naphthoquinone from Psychotria rubra and its structure-activity relationships.
AID663956Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay2012ACS medicinal chemistry letters, Feb-09, Volume: 3, Issue:2
Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists.
AID303300Cell viability in Raji cells at 10 mol ratio/TPA by tryptan blue staining relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID1754246Inhibition of recombinant Trypanosoma cruzi cruzain at 100 uM using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition measured for 5 mins by fluorimetric analysis relative to control
AID1322186Cytotoxicity against human ECA109 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Design, synthesis and biological evaluation of lapachol derivatives possessing indole scaffolds as topoisomerase I inhibitors.
AID618759Antitubercular activity against rifampicin-resistant Mycobacterium tuberculosis ATCC 35338 harboring His-526-Tri mutation in rpoB gene after 9 days by resazurin reduction assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Quinonoid and phenazine compounds: synthesis and evaluation against H37Rv, rifampicin and isoniazid-resistance strains of Mycobacterium tuberculosis.
AID1517763Inhibition of recombinant Cdc25A (unknown origin) using OMFP as substrate measured every 30 sec for 10 mins by fluorometric assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID303292Inhibition of TPA-induced EBV-EA activation in Raji cells at 1000 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID303298Cell viability in Raji cells at 500 mol ratio/TPA by tryptan blue staining relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID303297Cell viability in Raji cells at 1000 mol ratio/TPA by tryptan blue staining relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID663955Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay2012ACS medicinal chemistry letters, Feb-09, Volume: 3, Issue:2
Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists.
AID744768Cytotoxicity against Swiss mouse peritoneal macrophages after 24 hrs by MTT assay2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID1064153Growth inhibition of human Hs683 cells by MTT assay2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Growth inhibitory activity for cancer cell lines of lapachol and its natural and semi-synthetic derivatives.
AID451344Cytotoxicity against human Raji cells assessed as cell viability at 500 molar ratio after 48 hrs by trypan blue staining2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID714731Metabolic stability in in Wistar rat plasma assessed as alpha-lapachone level at 25 mg/kg after 1.5 hrs2012European journal of medicinal chemistry, Aug, Volume: 54Biomimetic in vitro oxidation of lapachol: a model to predict and analyse the in vivo phase I metabolism of bioactive compounds.
AID74123Inhibition constant of compound against binding of Yeast Glyoxalase I1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules.
AID618761Cytotoxicity against human PBMC after 72 hrs by Alamar blue assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Quinonoid and phenazine compounds: synthesis and evaluation against H37Rv, rifampicin and isoniazid-resistance strains of Mycobacterium tuberculosis.
AID1064151Growth inhibition of human PC3 cells by MTT assay2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Growth inhibitory activity for cancer cell lines of lapachol and its natural and semi-synthetic derivatives.
AID158816Inhibition of Plasmodium berghei infection in mice (Mus musculus) at 200 mg/kg peroral dose (expt 1)2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Antimalarial activity of phenazines from lapachol, beta-lapachone and its derivatives against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1858854Cytotoxicity against human MRC5 cells incubated for 24 hrs by MTT assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID1517779Cytotoxicity against human HL60 cells assessed as reduction in cell viability at <50 uM incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1322187Cytotoxicity against human HeLa cells assessed as decrease in cell proliferation after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Design, synthesis and biological evaluation of lapachol derivatives possessing indole scaffolds as topoisomerase I inhibitors.
AID660266Trypanocidal activity against bloodstream form of Trypanosoma cruzi Y isolated from albino mouse blood after 24 hrs by neubauer chamber analysis2012European journal of medicinal chemistry, Jun, Volume: 52On the search for potential anti-Trypanosoma cruzi drugs: synthesis and biological evaluation of 2-hydroxy-3-methylamino and 1,2,3-triazolic naphthoquinoidal compounds obtained by click chemistry reactions.
AID1517786Cytotoxicity against human PBMC cells assessed as reduction in cell viability at <50 uM incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (154)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (7.79)18.7374
1990's9 (5.84)18.2507
2000's36 (23.38)29.6817
2010's70 (45.45)24.3611
2020's27 (17.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.40 (24.57)
Research Supply Index5.12 (2.92)
Research Growth Index5.05 (4.65)
Search Engine Demand Index65.98 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews8 (4.82%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other158 (95.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]